Michelle is a versatile Development & Regulatory Strategist in all phases of drug development who has supported the virtual biotech model for the past 20 years and has conducted numerous health authority meetings (eg. Pre-IND Meetings) and successfully opened 50+ INDs/IMPDs/CTAs/NDAs in US, Europe, and Australia in many therapeutic areas (neuroscience, psychiatry, oncology, GI and cell/gene therapies).